Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Preventive Cardiology
Do you routinely recommend adding a nonstatin lipid-lowering agent for patients with ACS who are on maximally tolerated statin therapy and have an LDL-C between 55 and 69 mg/dL?
Related Questions
Would you prescribe a GLP-1 receptor agonist for an obese patient with low to moderate cardiovascular risk but a high CAC score?
How should we approach the recommendation of intermittent fasting for weight loss in patients with pre-existing cardiovascular conditions, given the observed association of increased CV mortality with eating durations of less than 8 hrs?
What should the LDL target be in patients with prediabetes and high lipoprotein (a) with family history of coronary artery disease?
Will TRYNGOLZA (olezarsen), recently approved for familial chylomicronemia syndrome, also lower triglycerides due to other genetic causes of hypertriglyceridemia?
What is a reasonable timeline for a left heart catheterization in a patient with newly diagnosed severe LV systolic dysfunction of unclear etiology and without an ACS presentation?
How would you approach the risk-benefit ratio of systemic anticoagulation in certain clinical scenarios such as atrial fibrillation or LV thrombus when a patient's history is also notable for type B aortic dissection or other aortic pathology such as aortic ulceration?
What is your approach to a newly diagnosed LBBB in individuals >70 years old who are free of any signs or symptoms of heart disease and without other significant ASCVD risk factors besides age?
Is there any indication/benefit for heparin in a patient with suspected type 2 myocardial infarction?
What would be your next diagnostic test of choice for a patient with findings concerning for silent ischemia on noninvasive functional testing in the absence of chest pain?
When would you consider switching to or adding on a PCSK9 inhibitor to lipid-lowering therapy following hospital discharge for acute coronary syndrome, in light of the results of the VICTORIAN-INCEPTION trial, provided LDL is still not at goal?
